A key distinction for oncologists is that PIK3CA mutations are typically "truncal" (present from baseline), whereas ESR1 mutations are "acquired" after exposure to aromatase inhibitors. This biological difference dictates when and how to test for each biomarker throughout a patient's treatment journey.

The Lidara study showed SERD benefit in patients without pre-existing ESR1 mutations. Success is likely multifactorial: SERDs are more effective and better tolerated than AIs. Critically, they also prevent the most common resistance mechanism—the acquisition of ESR1 mutations—from developing in the first place, altering the disease's future trajectory.

ESR1 mutations are rarely found in primary tumors but develop in metastatic settings under pressure from aromatase inhibitors, conferring resistance. This evolution necessitates serial, plasma-based genotyping upon each disease progression to identify these actionable mutations as they emerge.

The LIDERA trial's early, robust success with the oral SERD giredestrant in adjuvant therapy is surprising. In the metastatic setting, these drugs primarily benefit tumors with ESR1 mutations, which are acquired after therapy and rare at diagnosis. This paradoxical result suggests a different mechanism of action in early-stage disease and necessitates longer follow-up to confirm the finding.

The SERENA-6 study reveals that ESR1 mutations, a key resistance mechanism, emerge steadily throughout first-line aromatase inhibitor and CDK4/6 inhibitor therapy. This finding indicates that a single ctDNA test is inadequate. Instead, a strategy of continuous, serial monitoring is necessary to detect molecular relapse in real-time, posing a new paradigm for patient management.

An acquired ESR1 mutation in metastatic breast cancer, while indicating resistance to prior therapy, also confirms the tumor remains dependent on the estrogen receptor pathway. This paradoxical finding makes the mutation an ideal biomarker for predicting success with next-generation endocrine agents like oral SERDs.

ESR1 mutations in breast cancer are acquired alterations, meaning they can be missed by a single test. The speaker advocates for serial testing, especially after disease progression, using blood-based ctDNA analysis. This dynamic monitoring approach is essential for identifying patients who become eligible for targeted therapies over time.

Dr. Bardia emphasizes that ESR1 is an 'acquired alteration,' meaning the mutation can develop during treatment. This necessitates a shift from one-time diagnostic testing to a dynamic, serial testing model. Repeat testing is critical to identify these actionable mutations as they arise, allowing patients to access newly approved targeted therapies.

Not all mutations are equal. PIK3CA alterations are often present from the start (truncal mutations), indicating a more aggressive cancer. In contrast, ESR1 mutations are typically acquired later as a direct mechanism of resistance to endocrine therapy, making repeat testing after disease progression crucial.